The US court said that it would not review its decision to remove the injunction against Dr Reddy’s generic version of Indivior’s Suboxone Film product. Indivior warned that it faced “major disruption in the immediate future from a potential material and rapid loss of market share” to the generic rival. The company will seek to take the issue to the Supreme Court. However, Jefferies analysts said that it was unlikely to be successful in reversing the ruling. The shares fell 11¾p, or 10.4 per cent, to 101½p.

Source: The Times February 05, 2019 12:00 UTC